ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

— Johnson & Johnson is joining forces with San Diego-based ViaCyte Inc...